Since the pre-clinical studies showed no evidence of the off-tumor activity, the approach was advanced to a clinical trial, where CD37 CAR-T cells were evaluated in patients with relapsed or refractory CD37-positive hematologic malignancies (NCT04136275). This evidence concerns the gene CD37 and hematologic disorder.